Anhydroglucitol in Children With Type 1 Diabetes

ConditionDiabetes Mellitus, Type 1

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age2-18

SponsorUniversity Hospital, Geneva

About this trial

The investigators will measure blood levels of 1,5-anhydroglucitol in children with type 1 diabetes and correlate them with parameters related to functional beta-cell mass in diabetic patients. The values will be compared to those obtained in healthy volunteers. Children with newly diagnosed diabetes as well as children with longstanding disease will be included. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in type 1 diabetes.

Eligibility criteria

Qualifiers

Type 1 diabetes with positive autoantibodies against islets, insulin, islet antigen 2 (IA2), glutamic acid decarboxylase (GAD) 65 or zinc transporter (ZnT)8.

Treatment with continuous subcutaneous insulin infusion (CSII) with or without automated insulin delivery (AID).

Monitoring with a continuous glucose measurement system (CGMS) or flash glucose monitor (FGM).

Patient willing to keep the same type of CGMS or FGM during the year of observation

Disqualifiers

Patients treated with multiple daily injections (MDI) or not willing to wear a CGMS of FGM

Patients changing the type of CGMS during the course of the study.

Trial design

Treatments tested in this trial

Measurement of blood levels of 1,5-anhydroglucitol

Treatment groups

60 Participants

are divided into 2 treatment groups

Sponsors and collaborators

University Hospital, Geneva

Lead sponsor

University of Geneva, Switzerland

Collaborator

Source ClinicalTrials.gov